KL2 awards support mentored research career development for clinical investigators who have recently completed professional training and who are commencing basic, translational and/or clinical research. KL2 candidates are provided with a rich career development experience in a multidisciplinary setting.

Institutional Career Development (KL2) Program
The New Jersey Alliance for Clinical and Translational Science (NJ ACTS) solicited applications** for its Institutional Career Development (KL2) program in November 2020. The second class of KL2 Scholars will be appointed starting July 1, 2021.
 
The KL2 Program will issue a solicitation for its next cohort in late summer of 2022. Appointments would begin July 1, 2023.
This is an important opportunity for early stage faculty to be able to devote 80% effort to their projects, receive research funding and have the support of the community.
 
**2020 Application Components:
RFA for Translational Scientists: an abbreviated description of the program with a full list of the eligibility requirements.
Program Description:a detailed overview of the NJ ACTS KL2 Program, including information on current KL2 Scholars and a listing of the KL2 Program’s Academy of Mentors.
NJ ACTS KL2 Scholar Application: a fillable pdf to be submitted with the other required application materials.
Proposal Guidance and Requirements: a listing of the required components of a KL2 Scholar application packet.
NJ ACTS Junior Faculty Career Development Opportunities: NIH Diversity, Re-entry/Re-integration Supplements

NJ ACTS Diversity and Re-entry/Re-integration Supplements for Junior Faculty (Instructor and Assistant Professor) Program Information NJ ACTS (New Jersey Alliance for Clinical and Translational Research) is designed to improve the translational research process to get more treatments to more patients more quickly. Funded by NIH/NCATS under the Clinical and Translational Science Awards (CTSA) Program, NJ ACTS brings together Rutgers University, Princeton University and New Jersey Institute of Technology as the academic partners in the CTSA, and it works with NCATS and other CTSA’s on a national level. NJ ACTS acts as a catalyst for innovation in training, research tools and processes.

The purpose of this announcement is to alert you to the CTSA Program’s recently announced solicitation for diversity and re-entry/re-integration research supplements for junior faculty. The program creates opportunities for diversity in health-related research and reentry/re-integration into biomedical, behavioral, clinical, translational or social science research careers by providing career development funding.

At a Glance
 Internal Submission (pre-proposals) Deadline: September 24, 2021 [NIH Deadline: November 1, 2021]
Submit complete draft application to Tracey Sharp, KL2 Administrator, at kl2njacts@rbhs.rutgers.edu
 Candidates: Citizens or non-citizen nationals of the U.S. or individuals who have been lawfully admitted for permanent residence in the U.S. and meet the eligibility criteria described in the funding opportunity announcements.
 Award Budget: Up to $100,000/year for salary, plus fringe benefits. Costs may not exceed $150,000 direct costs after including funds for travel and limited supplies. The budget is based on the NIH RFA.

Read More about the Program

Prior KL2 Opportunities

2020 RFA – Second Cycle – NJ ACTS Translational Scientist Junior Faculty Award Program

 
Applications were solicited in November 2020, with the second class of KL2 Scholars appointed starting July 1, 2021.

Application components:
RFA for Translational Scientists: an abbreviated description of the program with a full list of the eligibility requirements.
Program Description:a detailed overview of the NJ ACTS KL2 Program, including information on current KL2 Scholars and a listing of the KL2 Program’s Academy of Mentors.
NJ ACTS KL2 Scholar Application: a fillable pdf to be submitted with the other required application materials.
Proposal Guidance and Requirements: a listing of the required components of a KL2 Scholar application packet.

NJ ACTS Diversity and Re-entry Supplements for Junior Faculty (Instructor and Assistant Professor)

 
Program Information – The CTSA Program is announcing diversity and re-entry research supplements, to promote opportunities for diversity in health-related research and re-entry into biomedical and behavioral research careers. The goal of these supplements is to build the clinical and translational research workforce that is prepared to improve the quality, safety, efficiency and speed of clinical and translational science research nationally.

What Do Diversity and Re-entry Supplements Offer?

  • Diversity supplements for junior faculty provide opportunity (salary, fringe benefits, travel and limited supplies) to improve the diversity of the research workforce by recruiting and supporting eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research.
  • Re-entry supplements provide opportunity (salary, fringe benefits, travel and limited supplies) to support individuals with high potential to re-enter an active research career after an interruption for family responsibilities or other qualifying circumstances.

Read the Full Document Here
Questions: Contact Tracey Sharp

 

KL2 Opportunity for Early Stage Investors

 

The NCCIH has issued a Notice of Special Interest [NOT-AT-20-010], which invites CTSA-funded Institutional Career Development (KL2) awardees to apply for an administrative supplement to fund one or more additional KL2 Scholars.
Letters of Intent due July 1,2020
NJ ACTS Early Stage Investor Opportunity